Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 19:8:782536.
doi: 10.3389/fmed.2021.782536. eCollection 2021.

The EU Response to the Presence of Nitrosamine Impurities in Medicines

Robin Ruepp  1 , Roland Frötschl  2 , Robert Bream  1 , Maria Filancia  1 , Thomas Girard  1 , Andrei Spinei  1 , Martina Weise  2 , Rhys Whomsley  1
Affiliations

The EU Response to the Presence of Nitrosamine Impurities in Medicines

Robin Ruepp et al. Front Med (Lausanne). .

Abstract

The unexpected detection of nitrosamine impurities in human medicines has recently seen global regulators act to understand the risks of these contaminations to patients and to limit their presence. Over 300 nitrosamines are known, many of which are highly potent mutagenic carcinogens. Regulators first became aware of the presence of nitrosamines in EU medicines in 2018, with reports of detection of N-nitroso-dimethylamine (NDMA) in valsartan from one manufacturer. A subsequent EU review of all valsartan medicines was triggered by the European Medicines Agency (EMA) and was later extended to other angiotensin receptor blockers/sartans. A separate review was also started for ranitidine medicines. This was followed by an EU-wide examination of the risk of presence of nitrosamines in all human medicines. This article reflects on the investigation of the EU regulatory network into the presence of nitrosamines and the scientific knowledge informing recommendations for developers on how to limit nitrosamines in medicines.

Keywords: carcinogenicity; human medicines; linear extrapolation; metformin; nitrite (NaNO2); nitrosamines; ranitidine; sartans.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. European Medicines Agency . Sartans Article 31 Referral. (2020). Available online at: https://www.ema.europa.eu/en/medicines/human/referrals/angiotensin-ii-re... (accessed September 22, 2021).
    1. European Medicines Agency . Ranitidine Art. 31 Referral. (2020). Available online at: https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-contai... (accessed September 22, 2021).
    1. European Medicines Agency . Nitrosamines Art. 5(3) Review Assessment Report. (2020). Available online at: https://www.ema.europa.eu/documents/referral/nitrosamines-emea-h-a53-149... (accessed September 22, 2021).
    1. European Medicines Agency . Nitrosamine Impurities Report. (2020). Available online at: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referra... (accessed September 22, 2021).
    1. King F, Searle AD, Urquhart MW. Ranitidine—investigations into the root cause for the presence of N-nitroso-N,N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products. Org Process Res Dev. (2020) 24:2915–26. 10.1021/acs.oprd.0c00462 - DOI